Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

Completed · Phase 1

Conditions studied: Cystic Fibrosis

In brief

The objectives of this study are to evaluate the effects of VX-770 on Midazolam and Rosiglitazone, and the effect of Fluconazole on VX-770.

Key facts

Study ID

NCT01060566

Run by

Vertex Pharmaceuticals Incorporated

People needed

24

Starts

2010-02-01

Expected to finish

2010-04-01

Last updated by the study team

2010-04-16

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects must be male or female and between 18 and 55 years of age.
• Subjects must be judged to be in good health.
• Subjects must have a body mass index (BMI) from 18 to 30 kg/m2.

You may not qualify if…

• History of any illness that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject.
• Subjects who have human immunodeficiency virus (HIV), hepatitis C, or active hepatitis B.
• Female subjects and female partner(s) of male subjects who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug.
• History of cardiovascular disease, hypoglycemia, or edema.

Where it is running

• Covan CRU, Inc. — Daytona Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.